Brain metastases from renal cell carcinoma. Should we change the current standard?

Cancer Treatment Reviews

Volumn 38, Issue 4, 2012, Pages 249-257

  Remon, Jordi ^a   Lianes, Pilar ^a   Martínez, Susana ^a  

^a HOSPITAL DE MATARÓ   (Spain)

Author keywords

Brain metastases; Multi targeted receptor tyrosine kinase inhibitors; Renal cell cancer; Sorafenib; Stereotactic radiosurgery; Sunitinib; VEGF inhibitors; Whole brain radiation therapy

Indexed keywords

ALPHA INTERFERON; BEVACIZUMAB; PAZOPANIB; SORAFENIB; SUNITINIB;

BLEEDING; BRAIN METASTASIS; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER SURVIVAL; CARDIOVASCULAR RISK; CENTRAL NERVOUS SYSTEM; DRUG EFFICACY; DRUG SAFETY; HEALTH CARE QUALITY; HUMAN; KIDNEY CARCINOMA; PATIENT SELECTION; PROGNOSIS; REVIEW; STEREOTACTIC RADIOSURGERY; TREATMENT RESPONSE;

BRAIN NEOPLASMS; CARCINOMA, RENAL CELL; HUMANS; KIDNEY NEOPLASMS;

EID: 84855988557     PISSN: 03057372     EISSN: 15321967     Source Type: Journal    
DOI: 10.1016/j.ctrv.2011.06.008     Document Type: Review

References (92)

1. Ferlay J., Shin H.R., Bray F., et al. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010, 127:2893-2917.
2. Parkin D.M., Bray F., Ferlay J., Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005, 55:74-108.
3. NCI. Cancer Trends Progress Report - 2009/2010 Update. 2011 [Accessed 18.01.11]. http://progressreport.cancer.gov/doc_detail.asp?pid=1&did=2009&chid=93&coid=920&mid=
4. Motzer R.J., Bander N.H., Nanus D.M. Renal-cell carcinoma. N Engl J Med 1996, 335:865-875.
5. Gavrilovic I.T., Posner J.B. Brain metastases: epidemiology and pathophysiology. J Neurooncol 2005, 75:5-14.
6. Smedby K.E., Brandt L., Backlund M.L., Blomqvist P. Brain metastases admissions in Sweden between 1987 and 2006. Br J Cancer 2009, 101:1919-1924.
7. Schouten L.J., Rutten J., Huveneers H.A., Twijnstra A. Incidence of brain metastases in a cohort of patients with carcinoma of the breast, colon, kidney, and lung and melanoma. Cancer 2002, 94:2698-2705.
8. Marshall M.E., Pearson T., Simpson W., Butler K., McRoberts W. Low incidence of asymptomatic brain metastases in patients with renal cell carcinoma. Urology 1990, 36:300-302.
9. Seaman E.K., Ross S., Sawczuk I.S. High incidence of asymptomatic brain lesions in metastatic renal cell carcinoma. J Neurooncol 1995, 23:253-256.
10. Hoshi S., Jokura H., Nakamura H., et al. Gamma-knife radiosurgery for brain metastasis of renal cell carcinoma: results in 42 patients. Int J Urol 2002, 9:618-625. (discussion 626; author reply 627).
11. Ljungberg B., Alamdari F.I., Rasmuson T., Roos G. Follow-up guidelines for nonmetastatic renal cell carcinoma based on the occurrence of metastases after radical nephrectomy. BJU Int 1999, 84:405-411.
12. Shuch B., La Rochelle J.C., Klatte T., et al. Brain metastasis from renal cell carcinoma: presentation, recurrence, and survival. Cancer 2008, 113:1641-1648.
13. Albiges L, Massard C, de La Motte Rouge T, et al. Brain metastases at screening in renal cell carcinoma: Prognosis and clinical implication. 2010 Genitourinary Cancers Symposium (Abstract No. 382) 2010.
14. Miller K.D., Weathers T., Haney L.G., et al. Occult central nervous system involvement in patients with metastatic breast cancer: prevalence, predictive factors and impact on overall survival. Ann Oncol 2003, 14:1072-1077.
15. Oh Y., Taylor S., Bekele B.N., et al. Number of metastatic sites is a strong predictor of survival in patients with nonsmall cell lung cancer with or without brain metastases. Cancer 2009, 115:2930-2938.
16. Taneja S., Talwar V., Jena A., Doval D.C. Incidence of asymptomatic brain metastasis in lung cancer patients at initial staging work-up - a study of 211 cases. JIACM 2007, 8:312-315.
17. Jena A., Taneja S., Talwar V., Sharma J.B. Magnetic resonance (MR) patterns of brain metastasis in lung cancer patients: correlation of imaging findings with symptom. J Thorac Oncol 2008, 3:140-144.
18. Aupérin A., Arriagada R., Pignon J.P., et al. Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic cranial irradiation overview collaborative group. N Engl J Med 1999, 341:476-484.
19. Seute T., Leffers P., Wilmink J.T., ten Velde G.P., Twijnstra A. Response of asymptomatic brain metastases from small-cell lung cancer to systemic first-line chemotherapy. J Clin Oncol 2006, 24:2079-2083.
20. NCCN Clinical Practice Guidelines in Oncology. Kidney Cancer. Version 1.2011. 2011 [Accessed January 2011]. http://www.nccn.org/.
21. Ruiz-Cerdá J.L., Jiménez Cruz F. Surgical treatment for renal cancer metastases. Actas Urol Esp 2009, 33:593-602.
22. Culine S., Bekradda M., Kramar A., et al. Prognostic factors for survival in patients with brain metastases from renal cell carcinoma. Cancer 1998, 83:2548-2553.
23. NCCN Clinical Practice Guidelines in Oncology. Central Nervous System Cancers. Version 1.2011. 2011 [Accessed January 2011]. http://www.nccn.org/.
24. Ewend M.G., Morris D.E., Carey L.A., Ladha A.M., Brem S. Guidelines for the initial management of metastatic brain tumors: role of surgery, radiosurgery, and radiation therapy. J Natl Compr Canc Netw 2008, 6:505-514.
25. Volpe A., Patard J.J. Prognostic factors in renal cell carcinoma. World J Urol 2010, 28:319-327.
26. Motzer R.J., Bacik J., Murphy B.A., Russo P., Mazumdar M. Interferon-alfa as a comparative treatment for clinical trials of new therapies against advanced renal cell carcinoma. J Clin Oncol 2002, 20:289-296.
27. Motzer R.J., Bukowski R.M., Figlin R.A., et al. Prognostic nomogram for sunitinib in patients with metastatic renal cell carcinoma. Cancer 2008, 113:1552-1558.
28. Heng D.Y., Xie W., Regan M.M., et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study. J Clin Oncol 2009, 27:5794-5799.
29. Sperduto P.W., Chao S.T., Sneed P.K., et al. Diagnosis-specific prognostic factors, indexes, and treatment outcomes for patients with newly diagnosed brain metastases: a multi-institutional analysis of 4259 patients. Int J Radiat Oncol Biol Phys 2010, 77:655-661.
30. Decker D.A., Decker V.L., Herskovic A., Cummings G.D. Brain metastases in patients with renal cell carcinoma: prognosis and treatment. J Clin Oncol 1984, 2:169-173.
31. Gaspar L., Scott C., Rotman M., et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys 1997, 37:745-751.
32. Gaspar L.E., Scott C., Murray K., Curran W. Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 2000, 47:1001-1006.
33. Patchell R.A., Tibbs P.A., Walsh J.W., et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med 1990, 322(8):494-500.
34. Vecht C.J., Haaxma-Reiche H., Noordijk E.M., et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery?. Ann Neurol 1993, 33(6):583-590.
35. Noordijk E.M., Vecht C.J., Haaxma-Reiche H., et al. The choice of treatment of single brain metastasis should be based on extracranial tumor activity and age. Int J Radiat Oncol Biol Phys 1994, 29(4):711-717.
36. Bindal R.K., Sawaya R., Leavens M.E., Lee J.J. Surgical treatment of multiple brain metastases. J Neurosurg 1993, 79(2):210-216.
37. Sawaya R., Hammoud M., Schoppa D., et al. Neurosurgical outcomes in a modern series of 400 craniotomies for treatment of parenchymal tumors. Neurosurgery 1998, 42:1044-1055. (discussion 1055-6).
38. Wronski M., Arbit E., Russo P., Galicich J.H. Surgical resection of brain metastases from renal cell carcinoma in 50 patients. Urology 1996, 47(2):187-193.
39. O'Dea M.J., Zincke H., Utz D.C., Bernatz P.E. The treatment of renal cell carcinoma with solitary metastases. J Urol 1978, 120(5):540-542.
40. Salvati M., Scarpinati M., Orlando E.R., et al. Single brain metastases from kidney tumors. Clinico-pathological considerations on a series of 29 cases. Tumori 1992, 78(6):392-394.
41. Cannady S.B., Cavanaugh B.S., Lee S.Y., et al. Results of whole brain radiotherapy and recursive partitioning analysis in patients with brain metastases from renall cell carcinoma: a retrospective study. Int J Rad Oncol Biol Phys 2004, 58(1):253-258.
42. Wronski M., Maor M.H., Davis B.J., Sawaya R., Levin V.A. External radiation of brain metastases from renal carcinoma: a retrospective study of 119 patients from the M.D. Anderson Cancer Center. Int J Radiat Oncol Biol Phys 1997, 37:753-759.
43. Shiau C.Y., Sneed P.K., Shu H.K., et al. Radiosurgery for brain metastases: relationship of dose and pattern of enhancement to local control. Int J Radiat Oncol Biol Phys 1997, 37:375-383.
44. Hernandez L., Zamorano L., Sloan A., et al. Gamma knife radiosurgery for renal cell carcinoma brain metastases. J Neurosurg 2002, 97(Suppl. 5):489-493.
45. Muacevic A., Kreth F.W., Mack A., et al. Stereotactic radiosurgery without radiation therapy providing high local tumor control of multiple brain metastases from renal cell carcinoma. Minim Invas Neurosurg 2004, 47:203-208.
46. Brown P.D., Brown C.A., Pollock B.E., et al. Stereotactic radiosurgery for patients with " radioresistant" brain metastases. Neurosurgery 2002, 51(3):656-665.
47. Marko N., Angelov L., Toms S., et al. Stereotactic radiosurgery as single-modality treatment of incidentally identified renal cell carcinoma brain metastases. World Neurosurg 2010, 73:186-193.
48. Muacevic A., Kreth F.W., Horstmann G.A., et al. Surgery and radiotherapy compared with gamma knife radiosurgery in the treatment of solitary cerebral metastases of small diameter. J Neurosurg 1999, 91:35-43.
49. Joseph J., Adler J.S., Cox R.S., Hancock S.L. Linear accelerator-based stereotaxic radiosurgery for brain metastases: the influence of number of lesions on survival. J Clin Oncol 1996, 14:1085-1092.
50. Blonigen B.J., Steinmetz R.D., Levin L., et al. Irradiated volume as a predictor of brain radionecrosis after linear accelerator stereotactic radiosurgery. Int J Radiat Oncol Biol Phys 2010, 77:996-1001.
51. Minniti G., Clarke E.L. Stereotactic radiosurgery for brain metastases: analysis of outcome and risk of brain radionecrosis. Radiat Oncol 2011, 15(6):48-50.
52. Shaw E., Scott C., Souhami L., et al. Single dose radiosurgical treatment of recurrent previously irradiated primary brain tumors and brain metastases. Final report of RTOG 9505. Int J Radiat Oncol Biol Phys 2000, 47:291-298.
53. Patchell R.A., Tibbs P.A., Regine W.F., et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. JAMA 1998, 280:1485-1489.
54. Kalkanis S.N., Kondziolka D., Gaspar L.E., et al. The role of surgical resection in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96:33-43.
55. Gaspar L.E., Mehta M.P., Patchell R.A., et al. The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol 2010, 96:17-32.
56. Andrews D.W., Scott C.B., Sperduto P.W., et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet 2004, 363:1665-1672.
57. Aoyama H., Shirato H., Tago M., et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. JAMA 2006, 295(21):2483-2491.
58. Kocher M., Soffietti R., Abacioglu U., et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22592-26001 study. J Clin Oncol 2011, 29:134-141.
59. Clarke J.W., Register S., McGregor J.M., et al. Stereotactic radiosurgery with or without whole brain radiotherapy for patients with single radioresistant brain metastases. Am J Clin Oncol 2010, 33:70-74.
60. Fokas E., Henzel M., Hamm K., et al. Radiotherapy for brain metastases from renal cell cancer: should whole-brain radiotherapy be added to stereotactic radiosurgery?: analysis of 88 patients. Strahlenther Onkol 2010, 186:210-217.
61. Tsao M.N., Lloyd N.S., Wong R.K., et al. Radiotherapeutic management of brain metastases: a systematic review and meta-analysis. Cancer Treat Rev 2005, 31:256-273.
62. Rades D., Heisterkamp C., Schild S.E. Do patients receiving whole-brain radiotherapy for brain metastases from renal cell carcinoma benefit from escalation of the radiation dose?. Int J Radiat Oncol Biol Phys 2010, 78:398-403.
63. Coppin C, Porzsolt F, Awa A, et al. Immunotherapy for advanced renal cell cancer. Cochrane Database Syst Rev 2005: CD001425.
64. Clark P.E. The role of VHL in clear-cell renal cell carcinoma and its relation to targeted therapy. Kidney Int 2009, 76:939-945.
65. Wiesener M.S., Munchenhagen P.M., Berger I., et al. Constitutive activation of hypoxia-inducible genes related to overexpression of hypoxia-inducible factor-1alpha in clear cell renal carcinomas. Cancer Res 2001, 61:5215-5222.
66. Choueiri T.K., Vaziri S.A., Jaeger E., et al. von Hippel-Lindau gene status and response to vascular endothelial growth factor targeted therapy for metastatic clear cell renal cell carcinoma. J Urol 2008, 180:860-865.
67. Forsythe J.A., Jiang B.H., Iyer N.V., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol Cell Biol 1996, 16:4604-4613.
68. Faivre S., Demetri G., Sargent W., Raymond E. Molecular basis for sunitinib efficacy and future clinical development. Nat Rev Drug Discov 2007, 6:734-745.
69. Yang F., Jove V., Xin H., et al. Sunitinib induces apoptosis and growth arrest of medulloblastoma tumor cells by inhibiting STAT3 and AKT signaling pathways. Mol Cancer Res 2010, 8:35-45.
70. Abouantoun T.J., Castellino R.C., MacDonald T.J. Sunitinib induces PTEN expression and inhibits PDGFR signaling and migration of medulloblastoma cells. J Neurooncol 2011, 101:215-226.
71. Hu S., Chen Z., Franke R., et al. Interaction of the multikinase inhibitors sorafenib and sunitinib with solute carriers and ATP-binding cassette transporters. Clin Cancer Res 2009, 15:6062-6069.
72. Glavinas H., Krajcsi P., Cserepes J., Sarkadi B. The role of ABC transporters in drug resistance, metabolism and toxicity. Curr Drug Deliv 2004, 1:27-42.
73. Motzer R.J., Hutson T.E., Tomczak P., et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. N Engl J Med 2007, 356:115-124.
74. Motzer R.J., Hutson T.E., Tomczak P., et al. Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma. J Clin Oncol 2009, 27:3584-3590.
75. Gore M.E., Szczylik C., Porta C., et al. Safety and efficacy of sunitinib for metastatic renal-cell carcinoma: an expanded-access trial. Lancet Oncol 2009, 10:757-763.
76. Gore M.E., Hariharan S., Porta C. Sunitinib in metastatic renal cell carcinoma patients with brain metastases. Cancer 2010, 117:501-509.
77. Stadler W.M., Figlin R.A., McDermott D.F., et al. Safety and efficacy results of the advanced renal cell carcinoma sorafenib expanded access program in North America. Cancer 2010, 116:1272-1280.
78. Larkin J.M., Hess V., Pickering L.M., et al. Symptomatic brain metastases from renal cell carcinoma during treatment with sunitinib or sorafenib. ASCO Meeting Abstr 2010, 28:e15023.
79. Massard C., Zonierek J., Gross-Goupil M., et al. Incidence of brain metastases in renal cell carcinoma treated with sorafenib. Ann Oncol 2010, 21:1027-1031.
80. Kamba T., McDonald D.M. Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 2007, 96:1788-1795.
81. Bitoh S., Hasegawa H., Ohtsuki H., et al. Cerebral neoplasms initially presenting with massive intracerebral hemorrhage. Surg Neurol 1984, 22:57-62.
82. Niizuma H., Nakasato N., Yonemitsu T., Ito S., Suzuki J. Intracerebral hemorrhage from a metastatic brain tumor. Importance of differential diagnosis preceding stereotaxic hematoma aspiration. Surg Neurol 1988, 29:232-236.
83. Escudier B., Bellmunt J., Negrier S., et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival. J Clin Oncol 2010, 28:2144-2150.
84. Rini B.I., Halabi S., Rosenberg J.E., et al. Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206. J Clin Oncol 2010, 28:2137-2143.
85. Ranpura V., Hapani S., Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. Jama 2011, 305:487-494.
86. Sternberg C.N., Davis I.D., Mardiak J., et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 2010, 28:1061-1068.
87. Breen E.C. VEGF in biological control. J Cell Biochem 2007, 102:1358-1367.
88. Byrne A.M., Bouchier-Hayes D.J., Harmey J.H. Angiogenic and cell survival functions of vascular endothelial growth factor (VEGF). J Cell Mol Med 2005, 9:777-794.
89. Carden C.P., Larkin J.M., Rosenthal M.A. What is the risk of intracranial bleeding during anti-VEGF therapy?. Neuro Oncol 2008, 10:624-630.
90. Je Y., Schutz F.A., Choueiri T.K. Risk of bleeding with vascular endothelial growth factor receptor tyrosine-kinase inhibitors sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. Lancet Oncol 2009, 10:967-974.
91. Scappaticci F.A., Skillings J.R., Holden S.N., et al. Arterial thromboembolic events in patients with metastatic carcinoma treated with chemotherapy and bevacizumab. J Natl Cancer Inst 2007, 99:1232-1239.
92. Choueiri T.K., Schutz F.A., Je Y., Rosenberg J.E., Bellmunt J. Risk of arterial thromboembolic events with sunitinib and sorafenib: a systematic review and meta-analysis of clinical trials. J Clin Oncol 2010, 28:2280-2285.